Oncotarget

Vol 5, No 3

February 15, 2014

View Archive »

Order a Reprint

About The Cover

Effect of Entolimod on 5-FU toxicity in IL-6 knockout mice. See Kojouharov et al.

Table of Contents

Editorial Materials

Targeting leukemia stem cells: in vitro veritas?

Targeting leukemia stem cells: in vitro veritas?

https://doi.org/10.18632/oncotarget.1777

Heather M. Bond, Maria Mesuraca,  and Giovanni Morrone
575-576
PDF  |  Order a Reprint

Reviews

Ras and autophagy in cancer development and therapy.

Ras and autophagy in cancer development and therapy.

https://doi.org/10.18632/oncotarget.1775

Eran Schmukler, Yoel Kloog,  and Ronit Pinkas-Kramarski
577-586
Abstract  |  PDF  |  HTML  |  Order a Reprint

Priority Research Papers

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers

https://doi.org/10.18632/oncotarget.1782

Huili Li, Katherine B. Chiappinelli, Angela A. Guzzetta, Hariharan Easwaran, Ray-Whay Chiu Yen, Rajita Vatapalli, Michael J. Topper, Jianjun Luo, Roisin M. Connolly, Nilofer S. Azad, Vered Stearns, Drew M. Pardoll, Nancy Davidson, Peter A. Jones, Dennis J. Slamon, Stephen B. Baylin, Cynthia A. Zahnow,  and Nita Ahuja
587-598
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Research Papers

A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity

A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity

https://doi.org/10.18632/oncotarget.1169

Matthew P Ablett, Ciara S O'Brien, Andrew H Sims, Gillian Farnie,  and Robert B Clarke
599-612
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Adipose-derived mesenchymal stem cells (ASCs) may favour breast cancer recurrence via HGF/c-Met signaling.

Adipose-derived mesenchymal stem cells (ASCs) may favour breast cancer recurrence via HGF/c-Met signaling.

https://doi.org/10.18632/oncotarget.1359

Vincenzo Eterno, Alberto Zambelli, Lorenzo Pavesi, Laura Villani, Vittorio Zanini, Gianfranco Petrolo, Stefania Manera, Antonella Tuscano,  and Angela Amato
613-633
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model

Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model

https://doi.org/10.18632/oncotarget.1596

Kodappully Sivaraman Siveen, Nurulhuda Mustafa, Feng Li, Radhamani Kannaiyan, Kwang Seok Ahn, Alan Prem Kumar, Wee-Joo Chng,  and Gautam Sethi
634-648
Abstract  |  PDF  |  HTML  |  Order a Reprint

Lymphoid enhancer binding factor-1 (LEF1) expression as a prognostic factor in adult acute promyelocytic leukemia

Lymphoid enhancer binding factor-1 (LEF1) expression as a prognostic factor in adult acute promyelocytic leukemia

https://doi.org/10.18632/oncotarget.1619

Francesco Albano, Antonella Zagaria, Luisa Anelli, Paola Orsini, Crescenzio F Minervini, Luciana Impera, Paola Casieri, Nicoletta Coccaro, Giuseppina Tota, Claudia Brunetti, Angela Minervini, Domenico Pastore, Paola Carluccio, Anna Mestice, Angelo Cellamare,  and Giorgina Specchia
649-658
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Large scale integration of drug-target information reveals poly-pharmacological drug action mechanisms in tumor cell line growth inhibition assays

Large scale integration of drug-target information reveals poly-pharmacological drug action mechanisms in tumor cell line growth inhibition assays

https://doi.org/10.18632/oncotarget.1597

Richard Knight, Mikhail Gostev, Sergei Ilisavskii, Anne E Willis, Gerry Melino,  and Alexey V Antonov
659-666
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer

Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer

https://doi.org/10.18632/oncotarget.1574

Nader Al Nakouzi, Sophie Cotteret, Frédéric Commo, Catherine Gaudin, Shanna Rajpar, Philippe Dessen, Philippe Vielh, Karim Fizazi,  and Anne Chauchereau
667-678
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

P-cadherin signals through the laminin receptor α6β4 integrin to induce stem cell and invasive properties in basal-like breast cancer cells

P-cadherin signals through the laminin receptor α6β4 integrin to induce stem cell and invasive properties in basal-like breast cancer cells

https://doi.org/10.18632/oncotarget.1459

André Filipe Vieira, Ana Sofia Ribeiro, Maria Rita Dionísio, Bárbara Sousa, Ana Nobre, André Albergaria, Angélica Santiago-Gómez, Nuno Mendes, Renê Gerhard, Fernando Schmitt, Robert Brian Clarke,  and Joana Paredes
679-692
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

AKT mediates actinomycin D-induced p53 expression

AKT mediates actinomycin D-induced p53 expression

https://doi.org/10.18632/oncotarget.1328

Chih-Shou Chen, Dong-Ru Ho, Fei-Yun Chen, Chang-Rong Chen, Yu-De Ke,  and Jyan-Gwo J Su
693-703
Abstract  |  PDF  |  HTML  |  Order a Reprint

Immunogenicity of targeted lentivectors

Immunogenicity of targeted lentivectors

https://doi.org/10.18632/oncotarget.1680

Cleo Goyvaerts, De Groeve Kurt, Sandra Van Lint, Carlo Heirman, Jo A. Van Ginderachter, Patrick De Baetselier, Geert Raes, Kris Thielemans,  and Karine Breckpot
704-715
Abstract  |  PDF  |  HTML  |  Order a Reprint

Cytotoxic effects of 15d-PGJ2 against osteosarcoma through ROS-mediated AKT and cell cycle inhibition

Cytotoxic effects of 15d-PGJ2 against osteosarcoma through ROS-mediated AKT and cell cycle inhibition

https://doi.org/10.18632/oncotarget.1704

Chueh-Chuan Yen, Chung-Der Hsiao, Wei-Ming Chen, Yao-Shan Wen, Yung-Chan Lin, Ting-Wei Chang, Fang-Yi Yao, Shih-Chieh Hung, Jir-You Wang, Jen-Hwey Chiu, Hsei-Wei Wang, Chi-Hung Lin, Tain-Hsiung Chen, Paul Chih-Hsueh Chen, Chien-Lin Liu, Cheng-Hwai Tzeng,  and Jonathan A. Fletcher
716-725
Abstract  |  PDF  |  HTML  |  Order a Reprint

Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma

Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma

https://doi.org/10.18632/oncotarget.1455

Arnau Montraveta, Silvia Xargay-Torrent, Mónica López-Guerra, Laia Rosich, Patricia Pérez-Galán, Itziar Salaverria, Silvia Beà, Susana G. Kalko, Mercè de Frias, Clara Campàs, Gaël Roué,  and Dolors Colomer
726-739
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Sp1-mediated microRNA-182 expression regulates lung cancer progression

Sp1-mediated microRNA-182 expression regulates lung cancer progression

https://doi.org/10.18632/oncotarget.1608

Wen-Bin Yang, Ping-Hsin Chen, Tsung-I Hsu, Tzu-Fun Fu, Wu-Chou Su, Hungjiun Liaw, Wen-Chang Chang,  and Jan-Jong Hung
740-753
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

MUC1-C nuclear localization drives invasiveness of renal cancer cells through a sheddase/gamma secretase dependent pathway

MUC1-C nuclear localization drives invasiveness of renal cancer cells through a sheddase/gamma secretase dependent pathway

https://doi.org/10.18632/oncotarget.1768

Audrey Bouillez, Viviane Gnemmi, Kelly Gaudelot, Brigitte Hémon, Bélinda Ringot, Nicolas Pottier, François Glowacki, Caroline Butruille, Christelle Cauffiez, Malika Hamdane, Nicolas Sergeant, Isabelle Van Seuningen, Xavier Leroy, Sébastien Aubert,  and Michaël Perrais
754-763
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer

Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer

https://doi.org/10.18632/oncotarget.1769

Francesco Crea, Akira Watahiki, Luca Quagliata, Hui Xue, Larissa Pikor, Abhijit Parolia, Yuwei Wang, Dong Lin, Wan L. Lam, William L. Farrar, Takao Isogai, Rudolf Morant, Serenella Castori-Eppenberger, Kim N. Chi, Yuzhuo Wang,  and Cheryl D. Helgason
764-774
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo

Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo

https://doi.org/10.18632/oncotarget.1770

Anna Goc, Belal Al-Husein Al-Husein, Katerina Katsanevas, Alison Steinbach, Uvette Lou, Harika Sabbineni, David L. DeRemer,  and Payaningal R. Somanath
775-787
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway

LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway

https://doi.org/10.18632/oncotarget.1772

Xiaoyan Li, Qifeng Yang, Haiyang Yu, Lihua Wu, Yuhan Zhao, Cen Zhang, Xuetian Yue, Zhen Liu, Hao Wu, Bruce G. Haffty, Zhaohui Feng,  and Wenwei Hu
788-801
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice

Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice

https://doi.org/10.18632/oncotarget.1773

Bojidar M. Kojouharov, Craig M. Brackett, Jean M. Veith, Christopher P. Johnson, Ilya I. Gitlin, Ilia A. Toshkov, Anatoli S. Gleiberman, Andrei V. Gudkov,  and Lyudmila G. Burdelya
802-814
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

PHLPP2 suppresses the NF-κB pathway by inactivating IKKβ kinase

PHLPP2 suppresses the NF-κB pathway by inactivating IKKβ kinase

https://doi.org/10.18632/oncotarget.1774

Nitin Kumar Agarwal, Xiaoping Zhu, Mihai Gagea, Charles L. White, Gilbert Cote,  and Maria-Magdalena Georgescu
815-823
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients

Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients

https://doi.org/10.18632/oncotarget.1776

Prashant K. Singh, Leah Preus, Qiang Hu, Li Yan, Mark D. Long, Carl D. Morrison, Mary Nesline, Candace S. Johnson, Shahriar Koochekpour, Manish Kohli, Song Liu, Donald L. Trump, Lara E. Sucheston-Campbell,  and Moray J. Campbell
824-840
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Hydrogen peroxide/ATR-Chk2 activation mediates p53 protein stabilization and anti-cancer activity of cheliensisin A in human cancer cells

Hydrogen peroxide/ATR-Chk2 activation mediates p53 protein stabilization and anti-cancer activity of cheliensisin A in human cancer cells

https://doi.org/10.18632/oncotarget.1780

Jingjie Zhang, Guangxun Gao, Liang Chen, Jingxia Li, Xu Deng, Qin-shi Zhao,  and Chuanshu Huang
841-852
Abstract  |  PDF  |  HTML  |  Order a Reprint

Frequent L1 retrotranspositions originating from TTC28 in colorectal cancer

Frequent L1 retrotranspositions originating from TTC28 in colorectal cancer

https://doi.org/10.18632/oncotarget.1781

Esa Pitkänen, Tatiana Cajuso, Riku Katainen, Eevi Kaasinen, Niko Välimäki, Kimmo Palin, Jussi Taipale, Lauri A. Aaltonen,  and Outi Kilpivaara
853-859
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint


Copyright © 2017 Impact Journals
Impact Journals is a registered trademark of Impact Journals, LLC